Plain-English translation of NCT06567197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a five-year study that follows people who have received autologous hematopoietic stem cell transplantation (aHSCT) for very active relapsing-remitting multiple sclerosis. Researchers want to understand how well this treatment works over the long term, how safe it is, and how it changes your immune system. You'll have regular check-ins with clinical tests, MRI scans, questionnaires, and blood work to track your progress.
Stem cell transplant is a serious but potentially life-changing treatment for aggressive multiple sclerosis, but doctors need more information about how well it works and stays safe over many years. This study will help them understand the long-term benefits and risks so they can better advise future patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll visit the hospital or clinic frequently over five years after your stem cell transplant. At each visit, doctors will do clinical exams, take blood samples, perform MRI brain scans, and ask you to fill out health questionnaires. These regular check-ins allow researchers to watch how your disease and immune system respond to the treatment over time.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Netherlands
Sponsor
Amsterdam UMC, location VUmc
Collaborators
St. Antonius Hospital
Enrollment target
~24 participants
Started
August 2023
Primary completion
September 2028
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Rick Heijnen, MSc
Amsterdam UMC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.